In patients with chronic kidney disease (CKD) and other MBDs, elevated FGF23 levels lead to hypophosphatemia and abnormal vitamin D metabolism, ultimately impairing normal mineral deposition and exacerbating skeletal pathology (Llorente-Pelayo et al., 2024). The gene discussed is FGF23; the disease is chronic kidney disease.